Related Experiment Video
Updated: Apr 22, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
17.0K
Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
Changhoon Yoo1, Dok Hyun Yoon1, Cheolwon Suh1
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Blood Research
|October 18, 2014
Summary
Serum beta-2 microglobulin (β2M) is an underestimated prognostic marker in malignant lymphomas. Recent studies confirm its potent predictive value, leading to its inclusion in new prognostic models for lymphomas like follicular lymphoma.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Beta-2 microglobulin (β2M) is a component of MHC class I antigens, present in nucleated cells.
- Its role as a non-invasive prognostic indicator in malignant lymphomas is often overlooked.
- Current therapeutic decisions rarely incorporate β2M levels.
Purpose of the Study:
- To review the evidence supporting serum β2M as a prognostic factor in malignant lymphomas.
- To discuss the future potential of β2M in lymphoma management.
Main Methods:
- Literature review of recent studies on serum β2M in malignant lymphomas.
- Analysis of studies incorporating β2M into prognostic models.
Main Results:
- Serum β2M is a potent prognostic marker across various malignant lymphoma subtypes.
- Recent studies with large patient cohorts validate its predictive significance.
- β2M has been integrated into a new prognostic model for follicular lymphoma.
Conclusions:
- Serum β2M demonstrates significant prognostic value in malignant lymphomas.
- Its underestimation in clinical practice warrants re-evaluation.
- Further research should explore expanded applications of β2M in lymphoma prognosis and treatment decisions.
